Shares of Korro Bio and Wave Life Sciences sank Monday after an analyst argued the former is the better way to play the ...

H.C. Wainwright analyst Mitchell Kapoor reiterated a Buy rating on Korro Bio (KRRO – Research Report) today and set a price target of ...

Fintel reports that on October 21, 2024, Raymond James initiated coverage of Korro Bio (NasdaqCM:KRRO) with a Strong Buy ...

Korro Bio (KRRO) announced a submission to the Bellberry HREC for a Phase 1/2 clinical study of KRRO-110 for AATD. A Clinical Advisory Board, ...

Shares of Korro Bio, Inc. (NASDAQ:KRRO – Get Free Report) have been assigned an average recommendation of “Buy” from the six brokerages that are currently covering the stock, MarketBeat reports.

Korro Bio stock opened at $70.02 on Monday. Korro Bio has a fifty-two week low of $9.15 and a fifty-two week high of $98.00. The stock’s fifty day moving average is $43.72 and its two-hundred ...

Antitrypsin Deficiency (AATD) submitted to Australian Bellberry Human Research Ethics Committee (HREC) -Clinical Advisory Board of lung and liver experts formed to support development of KRRO-110 ...

RBC Capital raised the firm’s price target on Korro Bio (KRRO) to $105 from $95 and keeps an Outperform rating on the shares. The firm notes that RNA editing data from Wave Life Sciences (WVE ...

Raymond James initiated coverage of Korro Bio (KRRO) with a Strong Buy rating and $153 price target The firm believes RNA editing will provide better therapeutic modality than DNA editing and/or ...

Korro Bio Inc. has announced a submission to the Australian Bellberry Human Research Ethics Committee (HREC) for a phase I/II study of KRRO-110 for α-1 antitrypsin deficiency (AATD).

Korro Bio, Inc. (NASDAQ:KRRO), a biotechnology company specializing in RNA editing, is making significant strides in the development of genetic medicines, particularly for Alpha-1 Antitrypsin ...